Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer
Sponsor: University Hospital Tuebingen
Collaborators: University Hospital Ulm|University Hospital Freiburg